Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
[EN] BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa<br/>[FR] BENZAMIDES ET INHIBITEURS ASSOCIES DU FACTEUR XA
申请人:COR THERAPEUTICS INC
公开号:WO2001064643A2
公开(公告)日:2001-09-07
Benzamide compounds of the formulae (VI) and (VII), where the variables are as defined in the claims, including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Combination product comprising melagatran and a factor xa inhibitor
申请人:AstrZeneca AB
公开号:US20030158120A1
公开(公告)日:2003-08-21
There is provided a combination product comprising: (A) melagatran or a pharmaceutically-acceptable derivative thereof; and (B) a Factor Xa inhibitor or a pharmaceutically-acceptable derivative thereof, wherein each components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, as well as the use of such a combination product in the treatment of a condition where anticoagulant therapy is indicated.
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.